Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, Hillegass J, Vacek PM, Pass HI, Mossman BT.

Clin Cancer Res. 2013 Apr 15;19(8):2071-83. doi: 10.1158/1078-0432.CCR-12-3202. Epub 2013 Feb 27.

PMID:
23446998
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.

Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT.

Int J Cancer. 2011 Sep 1;129(5):1075-86. doi: 10.1002/ijc.25763. Epub 2011 Jan 6.

PMID:
21710492
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.

Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT.

Mol Cancer. 2010 Dec 15;9:314. doi: 10.1186/1476-4598-9-314.

PMID:
21159167
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.

Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.

Int J Cancer. 2013 Jan 15;132(2):459-71. doi: 10.1002/ijc.27611. Epub 2012 May 17.

PMID:
22532243
[PubMed - indexed for MEDLINE]
5.

An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT.

Am J Respir Cell Mol Biol. 2011 Nov;45(5):906-14. doi: 10.1165/rcmb.2010-0282OC. Epub 2011 Mar 31.

PMID:
21454801
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Álvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparís-Ogando A, Pandiella A.

Clin Cancer Res. 2013 May 15;19(10):2677-87. doi: 10.1158/1078-0432.CCR-12-2118. Epub 2013 Mar 26.

PMID:
23532886
[PubMed - indexed for MEDLINE]
Free Article
7.

Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma.

Baldi A, Piccolo MT, Boccellino MR, Donizetti A, Cardillo I, La Porta R, Quagliuolo L, Spugnini EP, Cordero F, Citro G, Menegozzo M, Calogero RA, Crispi S.

PLoS One. 2011;6(8):e23569. doi: 10.1371/journal.pone.0023569. Epub 2011 Aug 17.

PMID:
21858171
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.

Cancer Sci. 2010 Sep;101(9):1955-64. doi: 10.1111/j.1349-7006.2010.01632.x.

PMID:
20608936
[PubMed - indexed for MEDLINE]
9.

Up-regulation of EphB4 in mesothelioma and its biological significance.

Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS.

Clin Cancer Res. 2005 Jun 15;11(12):4305-15.

PMID:
15958611
[PubMed - indexed for MEDLINE]
Free Article
10.

Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.

Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C, Smythe WR.

Int J Cancer. 2008 Jul 1;123(1):202-8. doi: 10.1002/ijc.23452.

PMID:
18360826
[PubMed - indexed for MEDLINE]
11.

TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D.

Clin Cancer Res. 2010 May 1;16(9):2591-604. doi: 10.1158/1078-0432.CCR-09-2443. Epub 2010 Apr 20.

PMID:
20406839
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.

Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J.

Int J Oncol. 2012 Aug;41(2):449-56. doi: 10.3892/ijo.2012.1462. Epub 2012 May 8.

PMID:
22580933
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.

Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL.

Oncogene. 2012 Aug 23;31(34):3889-900. doi: 10.1038/onc.2011.544. Epub 2011 Dec 5.

PMID:
22139075
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.

Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D.

Cancer Chemother Pharmacol. 2012 Feb;69(2):485-94. doi: 10.1007/s00280-011-1722-9. Epub 2011 Aug 13.

PMID:
21842204
[PubMed - indexed for MEDLINE]
15.

Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

Castro NE, Lange CA.

Breast Cancer Res. 2010;12(4):R60. doi: 10.1186/bcr2622. Epub 2010 Aug 5.

PMID:
20687930
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.

Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K.

Clin Cancer Res. 2011 May 1;17(9):2819-29. doi: 10.1158/1078-0432.CCR-10-2986. Epub 2011 Feb 28.

PMID:
21357681
[PubMed - indexed for MEDLINE]
Free Article
17.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

PMID:
19470734
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.

Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A.

Clin Cancer Res. 2008 Aug 15;14(16):5099-107. doi: 10.1158/1078-0432.CCR-08-0255.

PMID:
18698027
[PubMed - indexed for MEDLINE]
Free Article
19.

Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.

Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, Alexeyenko A, Hjerpe A, Dobra K.

PLoS One. 2012;7(10):e48091. doi: 10.1371/journal.pone.0048091. Epub 2012 Oct 29.

PMID:
23144729
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Ras pathway activation in malignant mesothelioma.

Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA.

J Thorac Oncol. 2007 Sep;2(9):789-95.

PMID:
17805054
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk